224 related articles for article (PubMed ID: 34052504)
1. The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK.
Yu M; Xu C; Zhang H; Lun J; Wang L; Zhang G; Fang J
Biochem Biophys Res Commun; 2021 Jul; 563():1-7. PubMed ID: 34052504
[TBL] [Abstract][Full Text] [Related]
2. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.
Yu T; An Q; Cao XL; Yang H; Cui J; Li ZJ; Xiao G
Life Sci; 2020 Nov; 260():118294. PubMed ID: 32818544
[TBL] [Abstract][Full Text] [Related]
3. Sphingosine kinase 1 plays a role in the upregulation of CD44 expression through extracellular signal-regulated kinase signaling in human colon cancer cells.
Kawahara S; Otsuji Y; Nakamura M; Murakami M; Murate T; Matsunaga T; Kanoh H; Seishima M; Banno Y; Hara A
Anticancer Drugs; 2013 Jun; 24(5):473-83. PubMed ID: 23426175
[TBL] [Abstract][Full Text] [Related]
4. Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Morii Y; Tsubaki M; Takeda T; Otubo R; Seki S; Yamatomo Y; Imano M; Satou T; Shimomura K; Nishida S
Eur J Pharmacol; 2021 May; 898():173957. PubMed ID: 33662352
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation.
Nemoto S; Nakamura M; Osawa Y; Kono S; Itoh Y; Okano Y; Murate T; Hara A; Ueda H; Nozawa Y; Banno Y
J Biol Chem; 2009 Apr; 284(16):10422-32. PubMed ID: 19240026
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
7. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
Wu YZ; Lin HY; Zhang Y; Chen WF
J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
[TBL] [Abstract][Full Text] [Related]
8. Effects of long non-coding RNA Opa-interacting protein 5 antisense RNA 1 on colon cancer cell resistance to oxaliplatin and its regulation of microRNA-137.
Liang J; Tian XF; Yang W
World J Gastroenterol; 2020 Apr; 26(13):1474-1489. PubMed ID: 32308348
[TBL] [Abstract][Full Text] [Related]
9. Metformin revert insulin-induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells.
Liu C; Liu Q; Yan A; Chang H; Ding Y; Tao J; Qiao C
Cancer Med; 2020 Jun; 9(11):3875-3884. PubMed ID: 32248666
[TBL] [Abstract][Full Text] [Related]
10. PTBP1 knockdown overcomes the resistance to vincristine and oxaliplatin in drug-resistant colon cancer cells through regulation of glycolysis.
Cheng C; Xie Z; Li Y; Wang J; Qin C; Zhang Y
Biomed Pharmacother; 2018 Dec; 108():194-200. PubMed ID: 30219676
[TBL] [Abstract][Full Text] [Related]
11. Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo.
Ozawa-Umeta H; Kishimoto A; Imaizumi A; Hashimoto T; Asakura T; Kakeya H; Kanai M
Cancer Sci; 2020 May; 111(5):1785-1793. PubMed ID: 32163218
[TBL] [Abstract][Full Text] [Related]
12. Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines.
Liu Z; Qiu M; Tang QL; Liu M; Lang N; Bi F
Chin J Cancer; 2010 Jul; 29(7):661-7. PubMed ID: 20591218
[TBL] [Abstract][Full Text] [Related]
13. Nitrogen permease regulator-like 2 enhances sensitivity to oxaliplatin in colon cancer cells.
Liu MN; Liu AY; Du YJ; Pei FH; Wang XH; Chen J; Liu D; Liu BR
Mol Med Rep; 2015 Jul; 12(1):1189-96. PubMed ID: 25777765
[TBL] [Abstract][Full Text] [Related]
14. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
15. Gfi-1 modulates HMGB1-Mediated autophagy to overcome oxaliplatin resistance in colorectal cancer.
Liu W; Zhang Z; Zhang L; Jiang X; Chen C; Wu X; Zhao Q
Heliyon; 2024 May; 10(9):e29859. PubMed ID: 38694127
[TBL] [Abstract][Full Text] [Related]
16. [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].
Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):566-570. PubMed ID: 28534337
[TBL] [Abstract][Full Text] [Related]
17. Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.
Xu J; Zeng LF; Shen W; Turchi JJ; Zhang ZY
Biochem Biophys Res Commun; 2013 Oct; 439(4):586-90. PubMed ID: 24041688
[TBL] [Abstract][Full Text] [Related]
18. [The effect of small GTPase Cdc42 on the multidrug resistance of oxaliplatin-resistant colon cancer cell lines].
Li NJ; Liu Z; Zhang Y; Yue CX; Wei W; Li LL; Tang QL; Bi F
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jul; 42(4):466-70. PubMed ID: 21866627
[TBL] [Abstract][Full Text] [Related]
19. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors.
Ahmed TA; Adamopoulos C; Karoulia Z; Wu X; Sachidanandam R; Aaronson SA; Poulikakos PI
Cell Rep; 2019 Jan; 26(1):65-78.e5. PubMed ID: 30605687
[TBL] [Abstract][Full Text] [Related]
20. Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells.
Park J; Lee GE; An HJ; Lee CJ; Cho ES; Kang HC; Lee JY; Lee HS; Choi JS; Kim DJ; Choi JS; Cho YY
Arch Pharm Res; 2021 Dec; 44(12):1091-1108. PubMed ID: 34750753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
